Generate Biomedicines, Inc. (GENB)

NASDAQ: GENB · Real-Time Price · USD

15.03

-0.06 (-0.40%)

At close: Aug 13, 2026, 4:00 PM EDT

15.13

+0.10 (0.67%)

Pre-market: Aug 14, 2026, 5:41 AM EDT

Generate Biomedicines Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	26.48	31.89	20.46
Revenue Growth	-	55.89%	-
Gross Profit	26.48	31.89	20.46
Selling, General & Admin	48.69	42.26	42.09
Research & Development	240.28	224.7	175.31
Total Operating Expenses	288.97	266.96	217.4
Operating Income	-262.49	-235.07	-196.94
Interest Income	13.13	13.66	18.12
Interest Expense	-0.8	-1.14	-2.12
Other Non-Operating Income (Expense)	-0.58	-0.26	-0.23
Total Non-Operating Income (Expense)	11.75	12.26	15.77
Pretax Income	-250.73	-222.8	-181.17
Provision for Income Taxes	-0.14	-0.16	-0.21
Net Income	-250.88	-222.97	-181.38
Minority Interest in Earnings	-13.14	-19.81	-7.61
Net Income Attributable to Preferred Dividends	30.93	46.37	40.01
Net Income to Common	-268.67	-249.52	-213.78
Net Income Growth	-	-	-
Shares Outstanding (Basic)	65	33	32
Shares Outstanding (Diluted)	65	33	32
Shares Change	-	2.77%	-
EPS (Basic)	-5.59	-7.57	-6.66
EPS (Diluted)	-5.59	-7.57	-6.66
EPS Growth	-	-	-
Free Cash Flow	-244.35	-204.13	-121.2
Free Cash Flow Growth	-	-	-
Free Cash Flow Per Share	-3.77	-6.19	-3.78
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-991.15%	-737.04%	-962.60%
Profit Margin	-947.32%	-699.10%	-886.57%
FCF Margin	-922.65%	-640.06%	-592.39%
EBITDA	-249.55	-221.89	-181.59
EBITDA Margin	-942.30%	-695.72%	-887.58%
EBIT	-262.49	-235.07	-196.94
EBIT Margin	-991.15%	-737.04%	-962.60%
Effective Tax Rate	0.06%	0.07%	0.12%

SEC Filings: 10-K · 10-Q